ArticleClinical rheumatology2026
Decreased salivary ZG16B expression is associated with exocrine dysfunction in Sjögren disease.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionSjögren disease (SjD) causes salivary hypofunction and ocular dryness. To investigate mechanisms of autoimmunity and salivation, we profiled unstimulated whole saliva from SjD patients and demographically matched controls by 4D-DIA proteomics and untargeted LC-MS/MS metabolomics.
methodUnstimulated whole saliva from patients meeting the 2016 ACR-EULAR criteria for SjD and demographically matched controls was profiled by 4D-DIA proteomics and untargeted LC-MS/MS metabolomics. An independent validation cohort (newly diagnosed SjD, n = 24; controls, n = 24) underwent ELISA for salivary ZG16B, a subset provided labial minor salivary gland (LSG) tissue for immunofluorescence (IF).
resultsProteomics identified 2032 differentially expressed proteins (1355 up; 677 down). Gene Ontology indicated downregulation of epithelial differentiation, structural maintenance, and epithelial tube formation, while KEGG highlighted enrichment of protein catabolism, immune regulation, and protein processing pathways. ZG16B was significantly reduced in SjD. Metabolomics detected 702 differential metabolites (307 up; 385 down); upregulated pathways involved protein digestion/absorption and multiple amino-acid metabolisms, whereas downregulated pathways mapped to aerobic respiration, suggesting reduced energy production. In validation, salivary ZG16B levels were markedly lower in newly diagnosed SjD than controls, and IF showed absent or sparse ZG16B-positive acinar cells in SjD LSG. Salivary ZG16B correlated positively with tear and salivary flow rates and inversely with focus score (FS).
conclusionsIntegrated proteo-metabolomic analysis reveals concurrent epithelial injury, immune activation, and compromised energy metabolism in SjD salivary glands. ZG16B downregulation is associated with exocrine dysfunction, supporting ZG16B as a promising noninvasive biomarker for SjD. Key Points • Saliva multi-omics reveals epithelial injury, immune activation, and metabolic impairment in SjD. • ZG16B is consistently downregulated in saliva and salivary gland epithelium. • ZG16B shows high diagnostic accuracy and mirrors gland function/histologic damage. • Dysregulated proteasomal and amino-acid pathways link molecular changes to secretory dysfunction.
Indexed as
Identifiers
41310095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.